Regeneron Announces FDA Review Acceptance of EYLEA’s sBLA for the treatment of Diabetic Retinopathy

 Regeneron Announces FDA Review Acceptance of EYLEA’s sBLA for the treatment of Diabetic Retinopathy

Regeneron Announces FDA Review Acceptance of EYLEA’s sBLA for the treatment of Diabetic Retinopathy

Shots:

  • The sBLA involves results of P-III PANORAMA trial assessing EYLEA treatment from moderate severe-to-severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME)
  • The announced PDUFA date for EYLEA by US FDA is 13 May, 2019. PANORAMA six months’ results has been announced in March 2018 with expected one year results in H2’18
  • EYLEA IV is currently approved in the US and indicated for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion, DME, and DR in patients with DME

Click here to read full press release/ article | Ref: Regeneron | Image: Market exclusive

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post